Morgan Stanley Initiates Coverage On Teva Pharmaceutical Indus with Equal-Weight Rating, Announces Price Target of $10
Portfolio Pulse from richadhand@benzinga.com
Morgan Stanley analyst Thibault Boutherin initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with an Equal-Weight rating and a price target of $10.
May 25, 2023 | 11:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley initiates coverage on Teva Pharmaceutical with an Equal-Weight rating and a price target of $10.
Morgan Stanley's initiation of coverage on Teva Pharmaceutical with an Equal-Weight rating and a price target of $10 indicates a neutral outlook for the stock. This news is directly related to TEVA and is important for investors, but the neutral rating suggests that the stock price may not experience significant short-term movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100